# Antioxidant Therapy in RYR1-Related Congenital Myopathy

> **NCT02362425** · PHASE1,PHASE2 · COMPLETED · sponsor: **National Institute of Nursing Research (NINR)** · enrollment: 63 (actual)

## Conditions studied

- Neuromuscular Disease

## Interventions

- **DRUG:** N-acetylcysteine
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02362425
- **Lead sponsor:** National Institute of Nursing Research (NINR)
- **Sponsor class:** NIH
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-02-12
- **Primary completion:** 2018-05-30
- **Final completion:** 2018-05-30
- **Target enrollment:** 63 (ACTUAL)
- **Last updated:** 2019-12-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02362425

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02362425, "Antioxidant Therapy in RYR1-Related Congenital Myopathy". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02362425. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*